TScan Therapeutics (TCRX) EBIT Margin (2020 - 2026)
TScan Therapeutics' (TCRX) quarterly EBIT Margin came in at 2901.33% in Q2 2026, down 164473.0% year-over-year from N/an in Q2 2025, and up 2.22% quarter-over-quarter from 2967.31% in Q1 2026.
Powered by 
Analysis
TScan Therapeutics (TCRX) EBIT Margin (2020 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has reported EBIT Margin for 7 consecutive years, with 2901.33% the latest figure, recorded in Q2 2026.
- On a quarterly basis, EBIT Margin fell 164473.0% year-over-year to 2901.33% in Q2 2026; TTM through Jun 2026 was 1695.15%, a 37692.0% increase from a year earlier, with the FY2025 full-year figure at 1315.38%, up 347230.0% from the prior year.
- EBIT Margin was 2901.33% for Q2 2026 at TScan Therapeutics, up from 2967.31% in the prior quarter.
- Over five years, EBIT Margin peaked at 296.17% in Q4 2023 and troughed at 6364.55% in Q2 2024.
- A 5-year average of 1988.51% and a median of 1093.01% in 2025 frame the typical range for EBIT Margin.
- Across the five-year window, EBIT Margin plunged 558279 bps in 2024 and jumped 510795 bps in 2025, its largest moves.
- Over 5 years, EBIT Margin stood at 602.55% in 2022, then jumped by 51 bps to 296.17% in 2023, then plunged by 1764 bps to 5520.6% in 2024, then surged by 83 bps to 929.41% in 2025, then plunged by 212 bps to 2901.33% in 2026.
- The last three EBIT Margin figures came in at 2901.33% (Q2 2026), 2967.31% (Q1 2026), and 929.41% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | 49.00% |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | -1,151.84% |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | -52.26% |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | 14.89% |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | -893.73% |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | -25,827.14% |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 41.18% |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | 3.31% |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | 0.56% |
| 10 | TScan Therapeutics | 42.91 Mn | 42.91 Mn | - | -2,901.33% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2,901.33% |
| Mar 31, 2026 | -2,967.31% |
| Dec 31, 2025 | -929.41% |
| Sep 30, 2025 | -1,475.59% |
| Jun 30, 2025 | -1,256.60% |
| Mar 31, 2025 | -1,669.74% |
| Dec 31, 2024 | -5,520.60% |
| Sep 30, 2024 | -3,109.82% |
| Jun 30, 2024 | -6,364.55% |
| Mar 31, 2024 | -5,542.93% |
| Dec 31, 2023 | -296.17% |
| Sep 30, 2023 | -636.69% |
| Jun 30, 2023 | -781.77% |
| Mar 31, 2023 | -334.31% |
| Dec 31, 2022 | -602.55% |
| Sep 30, 2022 | -492.95% |
| Jun 30, 2022 | -375.89% |
| Mar 31, 2022 | -535.02% |
| Dec 31, 2021 | -497.62% |
| Sep 30, 2021 | -656.80% |